Prescription Medicines
Monimate Tab.
- Product Category
- COX/5-LOX dual inhibitor anti-inflammatory analgesic
- Active Ingredients
- moniflumate
- Appearance
- A white to light yellow, elongated oval tablet.
- Reimbursement Code
- 648102910
01 / 02
1. Composition and Strength
- Active ingredient: Moniflumate (in-house specification)----350mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: sodium lauryl sulfate, microcrystalline cellulose, magnesium stearate, sodium starch glycolate, colloidal silicon dioxide, hydroxypropyl cellulose
2. Effectiveness
Analgesic and anti-inflammatory for the following diseases and symptoms
- Respiratory diseases (laryngitis, tracheitis, bronchitis)
- ENT diseases (sinusitis, otitis, tonsillitis, pharyngitis)
- Bone and joint disease
3. Dosage and dosage
Adults: As an initial dose, take 350 milligrams twice a day as moniflumate.
Depending on the patient, up to 700 mg per dose may be taken twice daily.
It is advisable to start with a low dose and increase the dose to the effective dose.
Increase or decrease appropriately depending on age and symptoms.
4. Precautions for use
1. Warning
1) If a person who regularly drinks three or more glasses of alcohol a day needs to take this medicine or another antipyretic analgesic, he or she must consult a doctor or pharmacist. If these people take this medicine, gastrointestinal bleeding may occur.
2) Cardiovascular risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious cardiovascular thrombotic reactions, myocardial infarction and stroke, which can be fatal. This risk may increase depending on the duration of administration. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.
Physicians and patients must carefully monitor the development of these cardiovascular symptoms, even if there is no history of cardiovascular disease. Patients should be informed in advance about signs and/or symptoms of serious cardiovascular toxicity and what measures to take if these symptoms occur.
3) Gastrointestinal risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious gastrointestinal adverse reactions, including gastric or intestinal bleeding, ulceration, and perforation, which may be fatal. These adverse reactions can occur at any time during the administration period without any past history or warning symptoms. Older adults may be at greater risk for these serious gastrointestinal adverse events and may have worse outcomes.
The longer the administration period, the more likely it is that serious gastrointestinal side effects will occur, but this risk cannot be completely ruled out during short-term administration.
While administering this drug, patients should be carefully monitored for symptoms and signs of gastrointestinal ulcers or bleeding, and if serious adverse gastrointestinal reactions are suspected, additional evaluation and treatment should be performed immediately. Discontinuing the administration of non-steroidal anti-inflammatory drugs until severe gastrointestinal side effects are completely ruled out can also be a treatment option. For patients at high risk, alternative treatments unrelated to NSAIDs should be considered.
4) Like other non-steroidal anti-inflammatory drugs, allergic reactions, including anaphylactoid reactions, can occur even without previous exposure to the drug.
5) Like other non-steroidal anti-inflammatory drugs, the pharmacological properties of this drug may suppress other symptoms and signs of inflammation, delaying the diagnosis of infectious complications under painful and non-infectious conditions.
2. Do not administer to the following patients.
1) Patients with peptic ulcer or its history
2) Patients with gastrointestinal bleeding or a history of it
3) Patients with severe blood abnormalities
4) Patients with severe liver impairment
5) Patients with severe renal impairment
6) Patients with severe cardiac dysfunction
7) Patients with severe hypertension
8) Patients with hypersensitivity to the components of this drug
9) Patients with a history of asthma, urticaria, or allergic reactions to aspirin or other non-steroidal anti-inflammatory drugs (including COX-2 inhibitors) (In these patients, severe and fatal anaphylactoid reactions have been rarely reported after administration of non-steroidal anti-inflammatory drugs.)
10) Treatment of pain occurring before and after coronary artery bypass surgery (CABG)
11) Pregnant and lactating women
12) Children and infants (safety for children, infants, and infants has not been established.)
13) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
3. Administer cautiously to the following patients.
1) Patients with blood abnormalities or a history of them
2) Patients with bleeding tendencies (platelet dysfunction may occur)
3) Patients with hepatic impairment or its history
4) Patients with renal impairment or its history
5) Patients with a history of hypersensitivity
6) Patients prone to decreased renal blood flow (patients with cardiac dysfunction, patients taking diuretics, patients with cirrhosis with ascites, after major surgery, the elderly, etc., as the effective circulating blood flow is reduced and renal blood flow is likely to decrease, which may cause renal failure)
7) Patients with high blood pressure (blood pressure may increase due to the tendency for Na and water retention due to the inhibition of prostaglandin synthesis)
8) Patients with cardiac dysfunction (since there is a tendency for Na and water retention due to the inhibition of prostaglandin synthesis, cardiac function may worsen)
9) SLE (systemic lupus erythematosus) patients and mixed connective tissue disease (MCTD) patients (can worsen SLE symptoms (renal dysfunction, etc.))
10) Patients with bronchial asthma (patients with bronchial asthma may include patients with aspirin asthma, so these patients may have severe asthma attacks.)
11) Patients with ulcerative colitis (there are reports that symptoms have worsened)
12) Patients with Crohn’s disease (there are reports that symptoms have worsened)
13) Patients with esophageal transit disorder (retention in the esophagus may cause esophageal ulcers)
14) Elderly people
4. Adverse reactions
1) Shock: In rare cases, shock symptoms (symptoms of shock, coldness, difficulty breathing, paralysis of the extremities, decreased blood pressure, edema, rash, itching, etc.) may appear. In such cases, stop administration and take appropriate measures.
2) Digestive system: Nausea, vomiting, stomach pain, heartburn, diarrhea, etc. may occur. These symptoms are dependent on the drug dose and most often occur during overdose. During long-term administration, peptic ulcer with bleeding or perforation, gastrointestinal bleeding (vomiting blood, hematochezia, bleeding, diarrhea), or esophageal ulcer may occur. In such cases, administration should be discontinued. In addition, sometimes anorexia, nausea, vomiting, stomach pain, indigestion, black stool, aphthous stomatitis, dry mouth, dry mucous membrane, bloody diarrhea, changes in appetite, pancreatitis, colitis, diarrhea abdominal cramps, abdominal bloating, stomach discomfort, very rarely aphthous gastritis, glossitis, esophageal lesions, diaphragmatic small intestine stricture, stomatitis, angular stomatitis, dry mouth, constipation, ulcerated stricture of small and large intestines, Lower intestinal disorders (non-specific hemorrhagic colitis, worsening of Crohn's disease or ulcerative colitis) may occur.
3) Blood: In rare cases, a decrease in granulocytes, a decrease in hemoglobin, a decrease in white blood cells, a decrease in platelets, anemia, aplastic anemia, hemolytic anemia, agranulocytosis, bleeding tendency, decrease in platelet function (prolongation of bleeding time), and increase in eosinophils may occur.
4) Skin: Rarely, skin rash, urticaria, herpes bullous, erythroderma (exfoliative dermatitis), purpura, allergic purpura, Stevens-Johnson syndrome (mucocutaneous ocular syndrome), Lyell syndrome (toxic epidermal necrosis), photosensitivity, redness, itching, eczema, dermatitis, angioedema, erythema multiforme, flushing, and exudative dermatitis may occur. In such cases, discontinue administration and take appropriate measures. Do it.
5) Liver: In rare cases, hepatitis, hepatitis with jaundice, jaundice, sometimes liver failure, and increased AST·ALT·ALP may occur. Very rarely, fulminant hepatitis may occur. Be especially careful when coadministering with contraindications.
6) Kidney: In rare cases, it may cause symptoms of acute renal failure (interstitial nephritis, renal papillary necrosis, etc.) (symptoms/test findings: oliguria, hematuria, proteinuria), nephrosis syndrome, and if hypercalcemia, hypoalbuminemia, interstitial nephritis, nephrotic syndrome, or in rare cases an increase in blood creatinine or sometimes an increase in BUN, discontinue administration immediately and take appropriate measures.
7) Hypersensitivity: In very rare cases, hypersensitivity reactions such as vasculitis, pneumonia, rarely asthma attacks, angioedema, anaphylactoid systemic reactions including low blood pressure, and sometimes rash, hives, etc. may occur. In such cases, discontinue administration and take appropriate measures.
8) Mental nervous system: As aseptic meningitis has been rarely reported, if symptoms such as severe headache, nausea, vomiting, insomnia, stiff neck, fever, or impaired consciousness appear, immediately discontinue administration and consult a doctor. In particular, administer with caution to patients with autoimmune diseases (SLE, MCTD). Additionally, insomnia, depression, irritability, anxiety, and double vision may occur. In rare cases, memory impairment, disorientation, nightmares, tremors, psychotic reactions, headache, drowsiness, dizziness, nervousness, paralysis, confusion, hallucinations, and convulsions may occur.
9) Sensory system: In rare cases, blurred vision, tinnitus, hearing impairment, taste impairment, transient pain, dryness, itchiness, and superficial keratitis may occur.
10) Circulatory system: In rare cases, increased blood pressure, decreased blood pressure, palpitations, tachycardia, congestive heart failure, ventricular extrasystoles, myocardial infarction, and chest pain may occur.
11) Respiratory system: Occasionally, epistaxis, severe asthma attacks, pharyngeal edema, and interstitial pneumonia may occur.
12) Urogenital system: In rare cases, oliguria, hematuria, proteinuria, frequent urination, enuresis, erectile dysfunction, vaginal bleeding, and nipple necrosis may occur.
13) Musculoskeletal system: Rhabdomyolysis (may occur in parallel with rapid deterioration of renal function; symptoms include muscle pain, weakness, increased creatine kinase, increased myoglobin in the blood or urine, etc.) may occur. In such cases, discontinue administration and take appropriate measures.
14) Others: Occasionally, edema, hair loss, rare general malaise, sweating, fever, chest pain, lip swelling, etc. may occur.
15) Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 6,499 patients over 6 years for re-examination in Korea, the incidence of adverse events was reported to be 4.86% (316/6,499, 368 cases) regardless of causal relationship. Among these, the rate of adverse drug reactions, which are adverse events in which a causal relationship with this drug cannot be ruled out, was 4.62% (300 people/6,499 people, 349 cases). Heartburn 0.78% (51 people/6,499 people, 51 cases), abdominal pain 0.71% (46 people/6,499 people, 46 cases), gastrointestinal disorder 0.68% (44 people/6,499 people, 44 cases), edema 0.58% (38 people/6,499 people, 38 cases), indigestion 0.45% (29 people/6,499 people, 29 cases), nausea 0.38% (25 people/6,499 people, 25 cases), abdominal discomfort 0.37% (24 people/6,499 people, 24 cases), facial edema 0.25% (16 people/6,499 people, 16 cases), vomiting It was reported in the order of 0.23% (15 people/6,499 people, 15 cases). Other reported adverse drug reactions are classified by body organ as follows.
- Gastrointestinal disorders: gastritis, abdominal distension, diarrhea, constipation, gastric ulcer, stomatitis, abdominal cramps, gastrointestinal bleeding
- Systemic abnormalities: weight gain, fever, no effect, peripheral edema
- Abnormalities in skin and appendages: rash, itching, hives
- Central and peripheral nervous system abnormalities: headache, dizziness
- Respiratory system abnormalities: wheezing, upper respiratory tract infection, difficulty breathing
- Cardiovascular abnormalities: palpitations, decreased blood pressure
- Urinary tract abnormalities: difficulty urinating, urinary incontinence, increased blood creatinine, increased BUN
- Metabolic and nutritional abnormalities: hyperglycemia, hypoglycemia
- Visual abnormalities: decreased vision
- Mental nervous system abnormalities: floating feeling, insomnia
The occurrence rate of unexpected adverse events that occurred during the domestic post-marketing surveillance period was 0.23% (15 people/6,499 people, 15 cases), weight gain 0.05% (3 people/6,499 people, 3 cases), no effect, wheezing, and visual acuity decrease each at 0.03% (2 people/6,499 people, 2 cases), upper respiratory tract infection, difficulty urinating, Urinary incontinence, hyperglycemia, hypoglycemia, and floating sensation were each 0.02% (1 person/6,499 people, 1 case). These were all adverse drug reactions whose causal relationship with this drug could not be ruled out. No serious adverse events that occurred during the domestic post-marketing surveillance period were reported.
5. General precautions
1) Before administering this drug, the potential risks and benefits of this drug and other alternative treatments should be considered. This drug is administered at the lowest effective dose for the shortest possible period consistent with the treatment goals of each patient.
2) Please note that treatment with anti-inflammatory painkillers is symptomatic treatment, not causative treatment.
3) When using for chronic diseases, consider the following:
① Patients taking this drug for a long period of time should regularly conduct clinical tests (urinalysis, blood tests such as complete blood count (CBC) and physicochemical tests, liver function tests, etc.), and if abnormalities are found, take appropriate measures such as reducing the dose or stopping medication. If clinical symptoms or systemic signs (e.g., eosinophilia, rash) related to liver or renal disease develop, or if abnormal liver or renal function test results persist or worsen, treatment with this drug should be discontinued.
② Consider treatments other than drug therapy.
4) When using for acute diseases, consider the following:
① Administer considering the degree of acute inflammation, pain, and fever.
② In principle, long-term administration of the same drug should be avoided.
③ If there is a causative treatment, implement it.
④ When used for colds and pharyngitis, the administration period is, in principle, within 5 days.
5) Observe the patient's condition sufficiently and pay attention to the occurrence of adverse reactions. Symptoms such as excessive decrease in body temperature, collapse, and cooling of extremities may occur, so pay special attention to the patient's condition after administration, especially in elderly patients with high fever and patients with consumptive diseases.
6) Due to the pharmacological properties of this drug, it may suppress other symptoms and signs of inflammation, delaying the diagnosis of infectious complications under painful and non-infectious conditions. When using this drug for inflammation caused by infection, it should be administered with caution, along with an appropriate antibacterial agent and sufficient observation.
7) Close medical observation should be performed on patients who show symptoms of gastrointestinal disease, have a history of gastrointestinal ulcers, ulcerative colitis, Crohn's disease, or liver dysfunction.
8) Patients with hepatic porphyria should be cautious when using this drug as it may cause seizures.
9) Gastrointestinal adverse reactions: Extreme caution should be exercised when prescribing non-steroidal anti-inflammatory drugs, including this drug, to patients with a history of ulcerative disease. In patients with a history of peptic ulcer disease and/or gastrointestinal bleeding, the risk of gastrointestinal bleeding increased more than 10 times when taking nonsteroidal anti-inflammatory drugs compared to patients without these risk factors. Other risk factors that increase gastrointestinal bleeding include concurrent use of oral corticosteroids or anticoagulants, long-term use of nonsteroidal anti-inflammatory drugs, alcohol consumption, old age, and poor health. Since most spontaneous reports of fatal gastrointestinal adverse reactions are in elderly and frail patients, special caution should be exercised when administering this drug to these patients.
10) High blood pressure: Non-steroidal anti-inflammatory drugs, including this drug, may cause high blood pressure or worsen existing high blood pressure, which may increase the incidence of adverse cardiovascular events. Patients taking thiazide diuretics or loop diuretics may have decreased response to these therapies when taking NSAIDs. Non-steroidal anti-inflammatory drugs, including this drug, should be administered with caution in patients with hypertension. Blood pressure should be closely monitored at the beginning and during treatment of this drug.
11) Congestive heart failure and edema: Fluid retention and edema have been observed in some patients taking non-steroidal anti-inflammatory drugs, including this drug. This drug should be administered with caution in patients with fluid retention or heart failure.
12) Long-term use of non-steroidal anti-inflammatory drugs may cause renal papillary necrosis or other kidney damage. In addition, since the role of prostaglandins is important in maintaining renal blood flow, special caution is required in patients with impaired heart or renal function, heart failure, renal failure, liver failure, patients taking diuretics or ACE inhibitors, the elderly, and patients with decreased cellularity due to any cause, such as before or after major surgical procedures. When using this drug in these cases, renal function should be tested as a preventive measure. When medication is stopped, most cases return to their pre-treatment state.
13) Advanced renal disease: No controlled clinical trials have been conducted on the use of this drug in patients with advanced renal disease. Therefore, administration of this drug is not recommended for patients with advanced renal disease. If treatment with this drug is to be initiated, the patient's renal function should be closely monitored.
14) Administration of non-steroidal anti-inflammatory drugs, including this drug, may result in an increase in liver function levels. These abnormal test values may worsen, remain unchanged, or be temporary as treatment continues. Additionally, serious liver-related adverse reactions, including jaundice, fatal fulminant hepatitis, liver necrosis, and liver failure (some of which were fatal), have been reported rarely with the administration of non-steroidal anti-inflammatory drugs, including this drug. Hepatitis can occur without prodromal symptoms.
For patients who have symptoms and/or signs suggestive of liver function abnormality, or whose liver function test results are abnormal or worsen, carefully observe whether liver function worsens during the treatment period. If clinical symptoms or systemic signs related to liver disease (e.g. eosinophilia, rash) appear, administration of this drug should be discontinued.
15) Since anemia may occur due to administration of non-steroidal anti-inflammatory drugs, including this drug, a hemoglobin level or hematocrit test should be performed if symptoms or signs of anemia appear due to long-term administration of this drug.
Non-steroidal anti-inflammatory drugs have been found to inhibit platelet aggregation and prolong bleeding time in some patients. Unlike aspirin, the effects of this drug on platelet function are relatively small, short-lived, and reversible. Patients who may be adversely affected by altered platelet function, such as those with coagulation-related diseases or those taking anticoagulants, or those with defects in hemostatic function, should be carefully monitored when receiving this drug.
16) Anaphylactoid reaction: Anaphylactoid reaction, such as swelling of the eyelids, lips, pharynx, and larynx, hives, asthma, bronchospasm, and decreased blood pressure, can occur even in patients who have not been exposed to the drug. This symptom complex typically occurs in patients with asthma who present with severe, potentially fatal bronchospasm with or without nasal polyps following administration of aspirin or other NSAIDs. If such an anaphylactoid reaction occurs, emergency treatment must be administered.
17) Skin reactions: This drug may cause serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, which may be fatal. These serious adverse reactions may occur without warning symptoms. In most cases, these adverse reactions occur within the first month of administration. Patients should be aware of serious skin signs and symptoms and should discontinue medication at the first sign or sign of skin rash or other hypersensitivity reaction.
18) Some asthma patients may react sensitively to aspirin. Aspirin use in patients with aspirin-sensitive asthma may be associated with severe bronchospasm, which can be fatal. Cross-reactivity, including bronchospasm, between aspirin and other NSAIDs has been reported in these aspirin-sensitive patients. Therefore, this drug should not be administered to aspirin-sensitive patients and should be used with caution in asthma patients.
19) This drug cannot be used as a replacement for corticosteroid preparations or as a drug to treat corticoid deficiency. Abrupt discontinuation of corticosteroids may result in worsening of corticosteroid-responsive disease. If this drug is to be administered to a patient who has been taking corticosteroids for a long period of time, the dose should be gradually reduced.
6. Interaction
1) It is advisable to avoid combined use with other anti-inflammatory analgesics. (When administered in combination with other non-steroidal anti-inflammatory drugs, the risk of gastrointestinal bleeding and peptic ulcers increases, and combined use with systemic non-steroidal anti-inflammatory drugs may increase the occurrence of adverse reactions.)
2) When administered in combination with glucocorticoids, the risk of gastrointestinal bleeding and peptic ulcer increases.
3) ACE inhibitors: There are reports that the antihypertensive effect of ACE inhibitors may be reduced by non-steroidal anti-inflammatory drugs, so this interaction should be kept in mind when administering this drug and ACE inhibitors together.
4) Aspirin: There is no consistent evidence that combined use with aspirin can reduce the risk of serious cardiovascular thrombotic events associated with the use of nonsteroidal anti-inflammatory drugs. As with other non-steroidal anti-inflammatory drugs, the combined use of this drug and aspirin may increase the risk of serious gastrointestinal adverse reactions, so the combined use of the two drugs is generally not recommended.
5) Diuretics (furosemide, etc.): Non-steroidal anti-inflammatory drugs tend to inhibit the activity of diuretics. Clinical trials and post-marketing studies have confirmed that the natriuretic effect of furosemide and thiazide diuretics may be reduced in some patients due to this drug's inhibition of prostaglandin synthesis in the kidney. Patients should be closely monitored for signs of renal failure during concurrent use of these drugs and nonsteroidal anti-inflammatory drugs.
When used in combination with furosemide and potassium-sparing diuretics, serum potassium concentration may increase, so it is necessary to test serum potassium concentration. Additionally, the interaction may be reduced when administered concurrently with thiazide diuretics.
6) Lithium: Non-steroidal anti-inflammatory drugs can increase serum lithium concentration and reduce renal clearance of lithium by inhibiting prostaglandin synthesis in the kidney. Therefore, when co-administering non-steroidal anti-inflammatory drugs and lithium preparations, the medication should be administered cautiously, such as reducing the dosage and carefully observing signs of lithium toxicity.
7) Methotrexate: Concurrent administration with non-steroidal anti-inflammatory drugs may increase the toxicity of methotrexate, so when administering the two drugs together, administer with caution, such as reducing the amount of the drug.
8) When administered in combination with digoxin, its action may be enhanced, so when used together, the drug should be administered with caution, such as reducing the amount of the drug.
9) Anticoagulants (warfarin, etc.): Warfarin and non-steroidal anti-inflammatory drugs may have a synergistic effect on gastrointestinal bleeding, so patients who use both drugs together may have an increased risk of severe gastrointestinal bleeding compared to those who take the two drugs alone. When administered in combination with anticoagulants, its action is enhanced, so it is necessary to reduce the combined dose.
10) The nephrotoxicity of cyclosporine may increase due to the effect of non-steroidal anti-inflammatory drugs on renal prostaglandins.
11) Cases of convulsive seizures presumed to be caused by the combined use of quinolone antibacterial agents and non-steroidal anti-inflammatory drugs have been reported very rarely.
7. Administration to pregnant women
1) There is no clinical data on administering this drug to pregnant women. Like other non-steroidal anti-inflammatory drugs, this drug may cause premature closure of the fetus's ductus arteriosus when administered late in pregnancy.
2) In experiments on rats, non-steroidal anti-inflammatory drugs, like other drugs that inhibit prostaglandin synthesis, increased the frequency of dystocia, delayed delivery, and decreased the survival rate of pups.
3) Since safety for pregnant women has not been established, it is administered to women who may become pregnant when the therapeutic benefits are judged to outweigh the risks.
8. Administration to elderly people
Elderly people are prone to adverse reactions, so start administration in small amounts, administer the minimum amount necessary, and administer carefully, paying particular attention to the occurrence of adverse reactions and observing the patient's condition.
9. Application precautions
1) Since it may collapse when it settles in the esophagus and cause esophageal ulcers, administer it with a large amount of water and be especially careful to administer it right before bedtime. Do not chew this medicine and do not take it on an empty stomach.
2) To reduce gastrointestinal disorders, take it immediately after a meal or with food, antacids, mucous membrane protectants, etc., or reduce the dose.
3) This drug may cause drowsiness and dull sensations, so caution is required when engaging in activities that require quick reflexes (driving, operating machinery, etc.).
10. Treatment in case of overdose
1) Signs and symptoms: Information on overdose is lacking, and typical clinical symptoms have not been established.
2) Treatment: This drug is rapidly hydrolyzed in the body to produce 2-〔3-(trifluoromethyl)-phenyl〕amino-3-pyridinecarboxylic acid, so in case of overdose, as is the case with all non-steroidal anti-inflammatory analgesics, the following measures are taken.
① Administer vomiting, aspiration of stomach contents, gastric lavage, activated charcoal, or saline laxatives as needed.
② Symptomatic treatment is administered for low blood pressure, renal failure, convulsions, gastrointestinal disorders, and respiratory depression. Special treatments such as forced diuresis and hemodialysis are not useful for elimination due to the high protein binding rate and extensive metabolism of NSAIDs.
11. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle, 100 tablets/bottle
7. Expiration date
36 months from date of manufacture
- Active ingredient: Moniflumate (in-house specification)----350mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: sodium lauryl sulfate, microcrystalline cellulose, magnesium stearate, sodium starch glycolate, colloidal silicon dioxide, hydroxypropyl cellulose
2. Effectiveness
Analgesic and anti-inflammatory for the following diseases and symptoms
- Respiratory diseases (laryngitis, tracheitis, bronchitis)
- ENT diseases (sinusitis, otitis, tonsillitis, pharyngitis)
- Bone and joint disease
3. Dosage and dosage
Adults: As an initial dose, take 350 milligrams twice a day as moniflumate.
Depending on the patient, up to 700 mg per dose may be taken twice daily.
It is advisable to start with a low dose and increase the dose to the effective dose.
Increase or decrease appropriately depending on age and symptoms.
4. Precautions for use
1. Warning
1) If a person who regularly drinks three or more glasses of alcohol a day needs to take this medicine or another antipyretic analgesic, he or she must consult a doctor or pharmacist. If these people take this medicine, gastrointestinal bleeding may occur.
2) Cardiovascular risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious cardiovascular thrombotic reactions, myocardial infarction and stroke, which can be fatal. This risk may increase depending on the duration of administration. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.
Physicians and patients must carefully monitor the development of these cardiovascular symptoms, even if there is no history of cardiovascular disease. Patients should be informed in advance about signs and/or symptoms of serious cardiovascular toxicity and what measures to take if these symptoms occur.
3) Gastrointestinal risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious gastrointestinal adverse reactions, including gastric or intestinal bleeding, ulceration, and perforation, which may be fatal. These adverse reactions can occur at any time during the administration period without any past history or warning symptoms. Older adults may be at greater risk for these serious gastrointestinal adverse events and may have worse outcomes.
The longer the administration period, the more likely it is that serious gastrointestinal side effects will occur, but this risk cannot be completely ruled out during short-term administration.
While administering this drug, patients should be carefully monitored for symptoms and signs of gastrointestinal ulcers or bleeding, and if serious adverse gastrointestinal reactions are suspected, additional evaluation and treatment should be performed immediately. Discontinuing the administration of non-steroidal anti-inflammatory drugs until severe gastrointestinal side effects are completely ruled out can also be a treatment option. For patients at high risk, alternative treatments unrelated to NSAIDs should be considered.
4) Like other non-steroidal anti-inflammatory drugs, allergic reactions, including anaphylactoid reactions, can occur even without previous exposure to the drug.
5) Like other non-steroidal anti-inflammatory drugs, the pharmacological properties of this drug may suppress other symptoms and signs of inflammation, delaying the diagnosis of infectious complications under painful and non-infectious conditions.
2. Do not administer to the following patients.
1) Patients with peptic ulcer or its history
2) Patients with gastrointestinal bleeding or a history of it
3) Patients with severe blood abnormalities
4) Patients with severe liver impairment
5) Patients with severe renal impairment
6) Patients with severe cardiac dysfunction
7) Patients with severe hypertension
8) Patients with hypersensitivity to the components of this drug
9) Patients with a history of asthma, urticaria, or allergic reactions to aspirin or other non-steroidal anti-inflammatory drugs (including COX-2 inhibitors) (In these patients, severe and fatal anaphylactoid reactions have been rarely reported after administration of non-steroidal anti-inflammatory drugs.)
10) Treatment of pain occurring before and after coronary artery bypass surgery (CABG)
11) Pregnant and lactating women
12) Children and infants (safety for children, infants, and infants has not been established.)
13) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
3. Administer cautiously to the following patients.
1) Patients with blood abnormalities or a history of them
2) Patients with bleeding tendencies (platelet dysfunction may occur)
3) Patients with hepatic impairment or its history
4) Patients with renal impairment or its history
5) Patients with a history of hypersensitivity
6) Patients prone to decreased renal blood flow (patients with cardiac dysfunction, patients taking diuretics, patients with cirrhosis with ascites, after major surgery, the elderly, etc., as the effective circulating blood flow is reduced and renal blood flow is likely to decrease, which may cause renal failure)
7) Patients with high blood pressure (blood pressure may increase due to the tendency for Na and water retention due to the inhibition of prostaglandin synthesis)
8) Patients with cardiac dysfunction (since there is a tendency for Na and water retention due to the inhibition of prostaglandin synthesis, cardiac function may worsen)
9) SLE (systemic lupus erythematosus) patients and mixed connective tissue disease (MCTD) patients (can worsen SLE symptoms (renal dysfunction, etc.))
10) Patients with bronchial asthma (patients with bronchial asthma may include patients with aspirin asthma, so these patients may have severe asthma attacks.)
11) Patients with ulcerative colitis (there are reports that symptoms have worsened)
12) Patients with Crohn’s disease (there are reports that symptoms have worsened)
13) Patients with esophageal transit disorder (retention in the esophagus may cause esophageal ulcers)
14) Elderly people
4. Adverse reactions
1) Shock: In rare cases, shock symptoms (symptoms of shock, coldness, difficulty breathing, paralysis of the extremities, decreased blood pressure, edema, rash, itching, etc.) may appear. In such cases, stop administration and take appropriate measures.
2) Digestive system: Nausea, vomiting, stomach pain, heartburn, diarrhea, etc. may occur. These symptoms are dependent on the drug dose and most often occur during overdose. During long-term administration, peptic ulcer with bleeding or perforation, gastrointestinal bleeding (vomiting blood, hematochezia, bleeding, diarrhea), or esophageal ulcer may occur. In such cases, administration should be discontinued. In addition, sometimes anorexia, nausea, vomiting, stomach pain, indigestion, black stool, aphthous stomatitis, dry mouth, dry mucous membrane, bloody diarrhea, changes in appetite, pancreatitis, colitis, diarrhea abdominal cramps, abdominal bloating, stomach discomfort, very rarely aphthous gastritis, glossitis, esophageal lesions, diaphragmatic small intestine stricture, stomatitis, angular stomatitis, dry mouth, constipation, ulcerated stricture of small and large intestines, Lower intestinal disorders (non-specific hemorrhagic colitis, worsening of Crohn's disease or ulcerative colitis) may occur.
3) Blood: In rare cases, a decrease in granulocytes, a decrease in hemoglobin, a decrease in white blood cells, a decrease in platelets, anemia, aplastic anemia, hemolytic anemia, agranulocytosis, bleeding tendency, decrease in platelet function (prolongation of bleeding time), and increase in eosinophils may occur.
4) Skin: Rarely, skin rash, urticaria, herpes bullous, erythroderma (exfoliative dermatitis), purpura, allergic purpura, Stevens-Johnson syndrome (mucocutaneous ocular syndrome), Lyell syndrome (toxic epidermal necrosis), photosensitivity, redness, itching, eczema, dermatitis, angioedema, erythema multiforme, flushing, and exudative dermatitis may occur. In such cases, discontinue administration and take appropriate measures. Do it.
5) Liver: In rare cases, hepatitis, hepatitis with jaundice, jaundice, sometimes liver failure, and increased AST·ALT·ALP may occur. Very rarely, fulminant hepatitis may occur. Be especially careful when coadministering with contraindications.
6) Kidney: In rare cases, it may cause symptoms of acute renal failure (interstitial nephritis, renal papillary necrosis, etc.) (symptoms/test findings: oliguria, hematuria, proteinuria), nephrosis syndrome, and if hypercalcemia, hypoalbuminemia, interstitial nephritis, nephrotic syndrome, or in rare cases an increase in blood creatinine or sometimes an increase in BUN, discontinue administration immediately and take appropriate measures.
7) Hypersensitivity: In very rare cases, hypersensitivity reactions such as vasculitis, pneumonia, rarely asthma attacks, angioedema, anaphylactoid systemic reactions including low blood pressure, and sometimes rash, hives, etc. may occur. In such cases, discontinue administration and take appropriate measures.
8) Mental nervous system: As aseptic meningitis has been rarely reported, if symptoms such as severe headache, nausea, vomiting, insomnia, stiff neck, fever, or impaired consciousness appear, immediately discontinue administration and consult a doctor. In particular, administer with caution to patients with autoimmune diseases (SLE, MCTD). Additionally, insomnia, depression, irritability, anxiety, and double vision may occur. In rare cases, memory impairment, disorientation, nightmares, tremors, psychotic reactions, headache, drowsiness, dizziness, nervousness, paralysis, confusion, hallucinations, and convulsions may occur.
9) Sensory system: In rare cases, blurred vision, tinnitus, hearing impairment, taste impairment, transient pain, dryness, itchiness, and superficial keratitis may occur.
10) Circulatory system: In rare cases, increased blood pressure, decreased blood pressure, palpitations, tachycardia, congestive heart failure, ventricular extrasystoles, myocardial infarction, and chest pain may occur.
11) Respiratory system: Occasionally, epistaxis, severe asthma attacks, pharyngeal edema, and interstitial pneumonia may occur.
12) Urogenital system: In rare cases, oliguria, hematuria, proteinuria, frequent urination, enuresis, erectile dysfunction, vaginal bleeding, and nipple necrosis may occur.
13) Musculoskeletal system: Rhabdomyolysis (may occur in parallel with rapid deterioration of renal function; symptoms include muscle pain, weakness, increased creatine kinase, increased myoglobin in the blood or urine, etc.) may occur. In such cases, discontinue administration and take appropriate measures.
14) Others: Occasionally, edema, hair loss, rare general malaise, sweating, fever, chest pain, lip swelling, etc. may occur.
15) Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 6,499 patients over 6 years for re-examination in Korea, the incidence of adverse events was reported to be 4.86% (316/6,499, 368 cases) regardless of causal relationship. Among these, the rate of adverse drug reactions, which are adverse events in which a causal relationship with this drug cannot be ruled out, was 4.62% (300 people/6,499 people, 349 cases). Heartburn 0.78% (51 people/6,499 people, 51 cases), abdominal pain 0.71% (46 people/6,499 people, 46 cases), gastrointestinal disorder 0.68% (44 people/6,499 people, 44 cases), edema 0.58% (38 people/6,499 people, 38 cases), indigestion 0.45% (29 people/6,499 people, 29 cases), nausea 0.38% (25 people/6,499 people, 25 cases), abdominal discomfort 0.37% (24 people/6,499 people, 24 cases), facial edema 0.25% (16 people/6,499 people, 16 cases), vomiting It was reported in the order of 0.23% (15 people/6,499 people, 15 cases). Other reported adverse drug reactions are classified by body organ as follows.
- Gastrointestinal disorders: gastritis, abdominal distension, diarrhea, constipation, gastric ulcer, stomatitis, abdominal cramps, gastrointestinal bleeding
- Systemic abnormalities: weight gain, fever, no effect, peripheral edema
- Abnormalities in skin and appendages: rash, itching, hives
- Central and peripheral nervous system abnormalities: headache, dizziness
- Respiratory system abnormalities: wheezing, upper respiratory tract infection, difficulty breathing
- Cardiovascular abnormalities: palpitations, decreased blood pressure
- Urinary tract abnormalities: difficulty urinating, urinary incontinence, increased blood creatinine, increased BUN
- Metabolic and nutritional abnormalities: hyperglycemia, hypoglycemia
- Visual abnormalities: decreased vision
- Mental nervous system abnormalities: floating feeling, insomnia
The occurrence rate of unexpected adverse events that occurred during the domestic post-marketing surveillance period was 0.23% (15 people/6,499 people, 15 cases), weight gain 0.05% (3 people/6,499 people, 3 cases), no effect, wheezing, and visual acuity decrease each at 0.03% (2 people/6,499 people, 2 cases), upper respiratory tract infection, difficulty urinating, Urinary incontinence, hyperglycemia, hypoglycemia, and floating sensation were each 0.02% (1 person/6,499 people, 1 case). These were all adverse drug reactions whose causal relationship with this drug could not be ruled out. No serious adverse events that occurred during the domestic post-marketing surveillance period were reported.
5. General precautions
1) Before administering this drug, the potential risks and benefits of this drug and other alternative treatments should be considered. This drug is administered at the lowest effective dose for the shortest possible period consistent with the treatment goals of each patient.
2) Please note that treatment with anti-inflammatory painkillers is symptomatic treatment, not causative treatment.
3) When using for chronic diseases, consider the following:
① Patients taking this drug for a long period of time should regularly conduct clinical tests (urinalysis, blood tests such as complete blood count (CBC) and physicochemical tests, liver function tests, etc.), and if abnormalities are found, take appropriate measures such as reducing the dose or stopping medication. If clinical symptoms or systemic signs (e.g., eosinophilia, rash) related to liver or renal disease develop, or if abnormal liver or renal function test results persist or worsen, treatment with this drug should be discontinued.
② Consider treatments other than drug therapy.
4) When using for acute diseases, consider the following:
① Administer considering the degree of acute inflammation, pain, and fever.
② In principle, long-term administration of the same drug should be avoided.
③ If there is a causative treatment, implement it.
④ When used for colds and pharyngitis, the administration period is, in principle, within 5 days.
5) Observe the patient's condition sufficiently and pay attention to the occurrence of adverse reactions. Symptoms such as excessive decrease in body temperature, collapse, and cooling of extremities may occur, so pay special attention to the patient's condition after administration, especially in elderly patients with high fever and patients with consumptive diseases.
6) Due to the pharmacological properties of this drug, it may suppress other symptoms and signs of inflammation, delaying the diagnosis of infectious complications under painful and non-infectious conditions. When using this drug for inflammation caused by infection, it should be administered with caution, along with an appropriate antibacterial agent and sufficient observation.
7) Close medical observation should be performed on patients who show symptoms of gastrointestinal disease, have a history of gastrointestinal ulcers, ulcerative colitis, Crohn's disease, or liver dysfunction.
8) Patients with hepatic porphyria should be cautious when using this drug as it may cause seizures.
9) Gastrointestinal adverse reactions: Extreme caution should be exercised when prescribing non-steroidal anti-inflammatory drugs, including this drug, to patients with a history of ulcerative disease. In patients with a history of peptic ulcer disease and/or gastrointestinal bleeding, the risk of gastrointestinal bleeding increased more than 10 times when taking nonsteroidal anti-inflammatory drugs compared to patients without these risk factors. Other risk factors that increase gastrointestinal bleeding include concurrent use of oral corticosteroids or anticoagulants, long-term use of nonsteroidal anti-inflammatory drugs, alcohol consumption, old age, and poor health. Since most spontaneous reports of fatal gastrointestinal adverse reactions are in elderly and frail patients, special caution should be exercised when administering this drug to these patients.
10) High blood pressure: Non-steroidal anti-inflammatory drugs, including this drug, may cause high blood pressure or worsen existing high blood pressure, which may increase the incidence of adverse cardiovascular events. Patients taking thiazide diuretics or loop diuretics may have decreased response to these therapies when taking NSAIDs. Non-steroidal anti-inflammatory drugs, including this drug, should be administered with caution in patients with hypertension. Blood pressure should be closely monitored at the beginning and during treatment of this drug.
11) Congestive heart failure and edema: Fluid retention and edema have been observed in some patients taking non-steroidal anti-inflammatory drugs, including this drug. This drug should be administered with caution in patients with fluid retention or heart failure.
12) Long-term use of non-steroidal anti-inflammatory drugs may cause renal papillary necrosis or other kidney damage. In addition, since the role of prostaglandins is important in maintaining renal blood flow, special caution is required in patients with impaired heart or renal function, heart failure, renal failure, liver failure, patients taking diuretics or ACE inhibitors, the elderly, and patients with decreased cellularity due to any cause, such as before or after major surgical procedures. When using this drug in these cases, renal function should be tested as a preventive measure. When medication is stopped, most cases return to their pre-treatment state.
13) Advanced renal disease: No controlled clinical trials have been conducted on the use of this drug in patients with advanced renal disease. Therefore, administration of this drug is not recommended for patients with advanced renal disease. If treatment with this drug is to be initiated, the patient's renal function should be closely monitored.
14) Administration of non-steroidal anti-inflammatory drugs, including this drug, may result in an increase in liver function levels. These abnormal test values may worsen, remain unchanged, or be temporary as treatment continues. Additionally, serious liver-related adverse reactions, including jaundice, fatal fulminant hepatitis, liver necrosis, and liver failure (some of which were fatal), have been reported rarely with the administration of non-steroidal anti-inflammatory drugs, including this drug. Hepatitis can occur without prodromal symptoms.
For patients who have symptoms and/or signs suggestive of liver function abnormality, or whose liver function test results are abnormal or worsen, carefully observe whether liver function worsens during the treatment period. If clinical symptoms or systemic signs related to liver disease (e.g. eosinophilia, rash) appear, administration of this drug should be discontinued.
15) Since anemia may occur due to administration of non-steroidal anti-inflammatory drugs, including this drug, a hemoglobin level or hematocrit test should be performed if symptoms or signs of anemia appear due to long-term administration of this drug.
Non-steroidal anti-inflammatory drugs have been found to inhibit platelet aggregation and prolong bleeding time in some patients. Unlike aspirin, the effects of this drug on platelet function are relatively small, short-lived, and reversible. Patients who may be adversely affected by altered platelet function, such as those with coagulation-related diseases or those taking anticoagulants, or those with defects in hemostatic function, should be carefully monitored when receiving this drug.
16) Anaphylactoid reaction: Anaphylactoid reaction, such as swelling of the eyelids, lips, pharynx, and larynx, hives, asthma, bronchospasm, and decreased blood pressure, can occur even in patients who have not been exposed to the drug. This symptom complex typically occurs in patients with asthma who present with severe, potentially fatal bronchospasm with or without nasal polyps following administration of aspirin or other NSAIDs. If such an anaphylactoid reaction occurs, emergency treatment must be administered.
17) Skin reactions: This drug may cause serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, which may be fatal. These serious adverse reactions may occur without warning symptoms. In most cases, these adverse reactions occur within the first month of administration. Patients should be aware of serious skin signs and symptoms and should discontinue medication at the first sign or sign of skin rash or other hypersensitivity reaction.
18) Some asthma patients may react sensitively to aspirin. Aspirin use in patients with aspirin-sensitive asthma may be associated with severe bronchospasm, which can be fatal. Cross-reactivity, including bronchospasm, between aspirin and other NSAIDs has been reported in these aspirin-sensitive patients. Therefore, this drug should not be administered to aspirin-sensitive patients and should be used with caution in asthma patients.
19) This drug cannot be used as a replacement for corticosteroid preparations or as a drug to treat corticoid deficiency. Abrupt discontinuation of corticosteroids may result in worsening of corticosteroid-responsive disease. If this drug is to be administered to a patient who has been taking corticosteroids for a long period of time, the dose should be gradually reduced.
6. Interaction
1) It is advisable to avoid combined use with other anti-inflammatory analgesics. (When administered in combination with other non-steroidal anti-inflammatory drugs, the risk of gastrointestinal bleeding and peptic ulcers increases, and combined use with systemic non-steroidal anti-inflammatory drugs may increase the occurrence of adverse reactions.)
2) When administered in combination with glucocorticoids, the risk of gastrointestinal bleeding and peptic ulcer increases.
3) ACE inhibitors: There are reports that the antihypertensive effect of ACE inhibitors may be reduced by non-steroidal anti-inflammatory drugs, so this interaction should be kept in mind when administering this drug and ACE inhibitors together.
4) Aspirin: There is no consistent evidence that combined use with aspirin can reduce the risk of serious cardiovascular thrombotic events associated with the use of nonsteroidal anti-inflammatory drugs. As with other non-steroidal anti-inflammatory drugs, the combined use of this drug and aspirin may increase the risk of serious gastrointestinal adverse reactions, so the combined use of the two drugs is generally not recommended.
5) Diuretics (furosemide, etc.): Non-steroidal anti-inflammatory drugs tend to inhibit the activity of diuretics. Clinical trials and post-marketing studies have confirmed that the natriuretic effect of furosemide and thiazide diuretics may be reduced in some patients due to this drug's inhibition of prostaglandin synthesis in the kidney. Patients should be closely monitored for signs of renal failure during concurrent use of these drugs and nonsteroidal anti-inflammatory drugs.
When used in combination with furosemide and potassium-sparing diuretics, serum potassium concentration may increase, so it is necessary to test serum potassium concentration. Additionally, the interaction may be reduced when administered concurrently with thiazide diuretics.
6) Lithium: Non-steroidal anti-inflammatory drugs can increase serum lithium concentration and reduce renal clearance of lithium by inhibiting prostaglandin synthesis in the kidney. Therefore, when co-administering non-steroidal anti-inflammatory drugs and lithium preparations, the medication should be administered cautiously, such as reducing the dosage and carefully observing signs of lithium toxicity.
7) Methotrexate: Concurrent administration with non-steroidal anti-inflammatory drugs may increase the toxicity of methotrexate, so when administering the two drugs together, administer with caution, such as reducing the amount of the drug.
8) When administered in combination with digoxin, its action may be enhanced, so when used together, the drug should be administered with caution, such as reducing the amount of the drug.
9) Anticoagulants (warfarin, etc.): Warfarin and non-steroidal anti-inflammatory drugs may have a synergistic effect on gastrointestinal bleeding, so patients who use both drugs together may have an increased risk of severe gastrointestinal bleeding compared to those who take the two drugs alone. When administered in combination with anticoagulants, its action is enhanced, so it is necessary to reduce the combined dose.
10) The nephrotoxicity of cyclosporine may increase due to the effect of non-steroidal anti-inflammatory drugs on renal prostaglandins.
11) Cases of convulsive seizures presumed to be caused by the combined use of quinolone antibacterial agents and non-steroidal anti-inflammatory drugs have been reported very rarely.
7. Administration to pregnant women
1) There is no clinical data on administering this drug to pregnant women. Like other non-steroidal anti-inflammatory drugs, this drug may cause premature closure of the fetus's ductus arteriosus when administered late in pregnancy.
2) In experiments on rats, non-steroidal anti-inflammatory drugs, like other drugs that inhibit prostaglandin synthesis, increased the frequency of dystocia, delayed delivery, and decreased the survival rate of pups.
3) Since safety for pregnant women has not been established, it is administered to women who may become pregnant when the therapeutic benefits are judged to outweigh the risks.
8. Administration to elderly people
Elderly people are prone to adverse reactions, so start administration in small amounts, administer the minimum amount necessary, and administer carefully, paying particular attention to the occurrence of adverse reactions and observing the patient's condition.
9. Application precautions
1) Since it may collapse when it settles in the esophagus and cause esophageal ulcers, administer it with a large amount of water and be especially careful to administer it right before bedtime. Do not chew this medicine and do not take it on an empty stomach.
2) To reduce gastrointestinal disorders, take it immediately after a meal or with food, antacids, mucous membrane protectants, etc., or reduce the dose.
3) This drug may cause drowsiness and dull sensations, so caution is required when engaging in activities that require quick reflexes (driving, operating machinery, etc.).
10. Treatment in case of overdose
1) Signs and symptoms: Information on overdose is lacking, and typical clinical symptoms have not been established.
2) Treatment: This drug is rapidly hydrolyzed in the body to produce 2-〔3-(trifluoromethyl)-phenyl〕amino-3-pyridinecarboxylic acid, so in case of overdose, as is the case with all non-steroidal anti-inflammatory analgesics, the following measures are taken.
① Administer vomiting, aspiration of stomach contents, gastric lavage, activated charcoal, or saline laxatives as needed.
② Symptomatic treatment is administered for low blood pressure, renal failure, convulsions, gastrointestinal disorders, and respiratory depression. Special treatments such as forced diuresis and hemodialysis are not useful for elimination due to the high protein binding rate and extensive metabolism of NSAIDs.
11. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle, 100 tablets/bottle
7. Expiration date
36 months from date of manufacture
Product Updates
Total 1items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 1 | Monimate Tab. | Monimate tablets (precautions for use) | 2012.02.28 | HWPPrecautions for using Monimate Tablet.hwp |